Policy News
-
Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act
Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT,…
-
CMS Again Delays Program to Expedite Coverage of Innovative Technologies
The Centers for Medicare & Medicaid Services (CMS) has once again delayed the January 14, 2021 final rule…
-
Who Develops Medicines? A New Study Highlights Role of Private Investment
Discussion around drug pricing often raises the issue of just how much NIH funding drives the development of…
-
House Energy and Commerce Committee Holds Hearing on Drug Price Controls
The House Energy and Commerce Health Subcommittee on Tuesday held a hearing on “Negotiating A Better Deal: Legislation…
-
Biden Supports IP Waiver for COVID-19 Vaccines
The Biden administration has announced that they will back a waiver of the WTO Trade-Related Aspects of Intellectual…
-
Biden’s First Address to Congress Calls for Giving Medicare Power to Negotiate Drug Prices
President Joe Biden’s first major joint address to Congress on Wednesday included calls to give Medicare the power to…
-
BioUtah Statement on House Democrat Leaders Drug Pricing Legislation
Salt Lake City, Utah (April 22, 2021) – BioUtah President and CEO, Kelvyn Cullimore, issued the following statement…
-
Life Sciences Company Valuation Webinar by Scalar & Now CFO
In case you missed the recent NOWCFO/Scalar webinar “What is Your Life Science or Bio Tech Company’s Worth?”,…
-
Study Analyzes Potential Impact of Drug Pricing Proposals
Congress is once again turning its attention to drug pricing, including the proposed use of foreign reference pricing…
-
President Biden Unveils Sweeping $2 Trillion Infrastructure Plan
On Wednesday, President Biden unveiled the first installment of his two-part Build Back Better plan – a sweeping…
-
BioUtah Urges MCIT Implementation
BioUtah has submitted a comment letter to CMS in response to concerns raised by the Biden administration around…
-
Impact of International Reference Pricing on Drug Innovation
Policymakers in Washington are considering plans to replace the current market-based system for pricing prescription medicines with a…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
